AHC
VIR icon

Anderson Hoagland & Co’s Vir Biotechnology VIR Stock Holding History

Anderson Hoagland & Co’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-33,550
Closed -$1.38M – 109
2020
Q3 		$1.38M Sell
33,550
-900
-3% -$38.7K 0.66% 41
2020
Q2 		$1.41M Buy
+34,450
New +$1.16M 0.66% 41

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Anderson Hoagland & Co's VIR Position: Q4 2020 in Review

Anderson Hoagland & Co sold out of Vir Biotechnology (VIR) in Q4 2020, closing a stake of 33,550 shares — an estimated $1.38M sold.

Anderson Hoagland & Co first reported a position in VIR in Q2 2020 and held it in 2 quarters. The position peaked at $1.41M in Q2 2020. 143 funds tracked by Wall St. Rank hold VIR as of Q4 2020.

  • Anderson Hoagland & Co reported no remaining Vir Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Anderson Hoagland & Co sold 33,550 Vir Biotechnology shares in Q4 2020, an estimated $1.38M.
  • Anderson Hoagland & Co first reported a position in Vir Biotechnology in Q2 2020 and held it in 2 quarters.
  • Anderson Hoagland & Co's Vir Biotechnology position peaked at $1.41M in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2020.

Based on Anderson Hoagland & Co's 13F filing for Q4 2020, filed 3 Feb 2021.